The Financial Times on Wednesday reported that Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days.

Pharmacyclics has earlier said that sales of Imbruvica, which has U.S. approvals for four forms of blood cancer, are expected to touch $1 billion in the United States this year.
Bloomberg reported last month that Pharmacyclics was mulling a sale and had attracted the interest of J&J and Novartis AG. Any interest from J&J would be logical, considering its already established relationship with Pharmacyclics, experts in the industry said.
Source-Medindia